Xenon Pharmaceuticals Inc. - 10-Q Filing
Xenon Pharmaceuticals Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2026, providing unaudited financial statements and operational updates. The filing includes details about asset acquisitions, equity offerings led by JPMorgan Securities LLC and other underwriters, and ongoing clinical programs such as XEN1701 and XEN1120 for pain management.
Tickers: $XENE